Business Wire

PCI Pharma Services Opens New England Center of Excellence to Bring Global Clinical Supply Capabilities to New England

Share

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, the first facility of its kind to support the growing needs of global developers of biologics in the New England region. The new facility will provide increased flexibility and scalability for secondary packaging, distribution and cold chain storage of innovative therapies in development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005234/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rendering of the new PCI facility in Bridgewater, MA. (Photo: Business Wire)

“As the northeast biopharma market continues to grow, we are bringing distinctive clinical supply capabilities to the backyard of product development, creating a personalized and responsive approach to evolving client needs,” said Salim Haffar, CEO, PCI Pharma Services. “This newest facility follows our growth in facilities in Berlin, Germany, and Rockford, Illinois, and will create significant local job growth potential.”

To keep pace with the growth in biologics and gene therapies, which require cold chain infrastructure including deep freeze, the new facility has a capacity for a -20°C freezer, 35 ultra-low temperature freezers at -80°C and 12 liquid nitrogen freezers. The Center of Excellence also features a temperature-controlled room containing a 5,000 square foot cooler at 2° to 8°C, each with five levels of warehouse racking. A 1000-square-foot cold secondary packaging room will eventually be converted to primary packaging with the planned construction of an additional secondary packing unit.

“Boston is a booming biotech market with hundreds of local organizations developing new compounds in the biologics space,” said Craig LaMarca, General Manager of Boston Clinical Trial Services, PCI Pharma Services. “The facility features leading technologies and capabilities, making it a crucial component to help our clients deliver life-saving therapies to patients safely and efficiently.”

PCI currently occupies 50,000 square feet of the new 100,000 square foot building, with the remaining space available for lease. The campus was constructed to reflect Environmental Social Governance (ESG) and sustainability efforts. These features include a complex stormwater runoff system with a series of ponds that filter the water before it leaves the site, an underground oil and sedimentation separation tank, electric vehicle chargers and the exclusive use of LED lighting throughout the building.

The opening of the New England Center of Excellence marks the latest in a series of worldwide expansions for PCI including six sites across three continents, including Bedford, New Hampshire; Berlin, Germany; San Diego, California; Rockford, Illinois; and Melbourne, Australia. In February 2022, PCI sites in San Diego and Melbourne added innovative equipment with aseptic fill-finish capabilities to enhance PCI’s global offerings and deliver much-needed capacity to early-phase clinical clients.

For more information on PCI’s aseptic fill-finish and lyophilization capabilities, please click here.

About PCI Pharma Services

PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ty Guzman-Touchberry, WE Communications
tgtouchberry@we-worldwide.com / +1-212-551-4877

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye